Tous Actualités
Suivre
Abonner Solianis Monitoring AG

Solianis Monitoring AG

Non-invasive glucose monitoring - Solianis Monitoring AG Breakthrough home use study finalized - Board of Directors reinforce

Zurich (ots)

Solianis has just finalized a test series in which
patients with diabetes have worn the first configuration of the
multisensor system for non-invasive Continuous Glucose Monitoring at
home and at work. Results show that the system tracks glucose in
these settings and that it is sensitive to hyper- and hypoglycemic
glucose excursions.
"This is the first study ever performed with any non-invasive
glucose sensor in a home use environment. The data show clearly that
the technology works and that we are on our way to the final product"
says Mario Stark, CEO of Solianis. The company expects to launch its
first product in Europe in 2010 after CE approval, targeting this
non-invasive device at the insulin dependent diabetes population.
Later model variants will address patients with diabetes and impaired
glucose tolerance.
To move forward with the implementation of the prototype and set
up the market introduction, Solianis has strengthened its Board of
Directors with two renowned industry experts:
Dr. Russ Potts holds a PhD in Biochemistry. He worked at Pfizer on
transdermal drug delivery and at Cygnus as Vice President R&D until
2002. Cygnus developed the first FDA-approved, minimally-invasive,
continuous glucose monitor "Glucowatch". At Cygnus his
responsibilities included FDA technical liaison & fund raising, with
strategic as well as technical input. Today he is a consultant for
drug delivery and glucose monitoring devices. His role at Solianis
will include technical and patent support, recommendations for the
approach to the FDA and strategic planning.
Dr. Anders Weber holds a Ph.D. in Immunology from the Royal
Veterinary and Agricultural University of Copenhagen, and he has
performed his post doctorate studies on optical immunosensors at the
University of Michigan, Ann Arbor, and the Biotechnology Centre in
Pittsburgh. He started his industrial career as Development Engineer
at Radiometer A/S in Copenhagen as part of a team developing
amperometric glucose and lactate sensors and subsequently headed the
advanced Sensors Development Unit. In various capacities, he
initiated and managed 12 start-up companies on behalf of Danish
Development Finance Corporation and other investors.
Solianis Monitoring AG is a medical devices company developing a
non-invasive Continuous Glucose Monitor (CGM) for self-monitoring
patients with diabetes.  Its technology is based on a unique and
proprietary multisensor technology for monitoring physiological
parameters.  It was incorporated in May 2005, and it is funded by
private investors and the Pioneer Fund of the Cantonal Bank of
Zürich. The Solianis' non-invasive device delivers comparable results
to the minimally invasive devices currently approved by the FDA.

Contact:

Mario Stark, CEO
Phone: +41/44/306'80'40
Mobile: +41/79/542'88'74
E-Mail: mario.stark@solianis.com
Internet: www.solianis.com

Plus de actualités: Solianis Monitoring AG
Plus de actualités: Solianis Monitoring AG